<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165070</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Anticoagulant therapy duration. In favour of short-term courses</dc:title>
<dc:description xml:lang="en">In recent years, we have observed a tendency to extend anticoagulant therapy for patients with venous thromboembolism disease (VTE). This practice exposes patients to a greater risk of severe and fatal haemorrhage, which, in certain conditions, outweighs the benefits related to the reduction in disease recurrence. This review examines the evidence in favour of reducing anticoagulant therapy as much as possible, especially for patients with VTE 'caused' by temporary risk factors, with isolated deep vein thrombosis and with unprovoked VTE and a high risk of haemorrhage (AU)</dc:description>
<dc:creator>Nieto Rodríguez, JA</dc:creator>
<dc:creator>Ramírez Luna, JC</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Durante los últimos años se ha observado una tendencia a prolongar la duración del tratamiento anticoagulante en los pacientes con enfermedad tromboembólica venosa (ETEV). Esto expone a los pacientes a un mayor riesgo de hemorragias graves y mortales que, en determinadas situaciones, superan los beneficios relacionados con la reducción de recurrencias de la enfermedad. En esta revisión se repasan las evidencias a favor de reducir al mínimo el tratamiento anticoagulante, especialmente en los pacientes con ETEV «provocada» por factores de riesgo transitorios, con trombosis venosa profunda aislada, y con ETEV «no provocada» y riesgo alto de hemorragia (AU)</dc:description>
<dc:source>Rev Clin Esp;217(6): 365-369, ago.-sept. 2017. graf, tab</dc:source>
<dc:identifier>ibc-165070</dc:identifier>
<dc:title xml:lang="es">Duración del tratamiento anticoagulante. A favor de plazos cortos</dc:title>
<dc:subject>^d6622^s22067</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d52618^s22067</dc:subject>
<dc:subject>^d52618^s22012</dc:subject>
<dc:subject>^d12428</dc:subject>
<dc:subject>^d6622^s22047</dc:subject>
<dc:subject>^d52618^s22016</dc:subject>
<dc:subject>^d932^s22000</dc:subject>
<dc:subject>^d12092^s22062</dc:subject>
<dc:subject>^d1784^s22074</dc:subject>
<dc:subject>^d12092^s22047</dc:subject>
<dc:subject>^d12092^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201709</dc:date>
</metadata>
</record>
</ibecs-document>
